235 related articles for article (PubMed ID: 9205742)
21. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
Gabryelewicz A; Czajkowski A; Skrodzka D; Marlicz K; Luca de Tena F; Aldeguer M; Chantar C; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
[TBL] [Abstract][Full Text] [Related]
23. Effects of the novel histamine H2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-[2-[[[5- (methylamino)methyl-2-furyl]methyl]thio]ethyl]-2-(methylsulfonyl) guanidine on gastric secretion and gastroduodenal ulcers in rats.
Amagase K; Kato S; Yamamoto H; Okabe S
Arzneimittelforschung; 1996 Feb; 46(2):177-84. PubMed ID: 8720310
[TBL] [Abstract][Full Text] [Related]
24. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
25. Carcinogenicity studies on ebrotidine.
Romero A; Rives A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):515-9. PubMed ID: 9205755
[TBL] [Abstract][Full Text] [Related]
26. In vitro anti-Helicobacter pylori activity of ebrotidine.
Palacín C; Tarragó C; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):471-4. PubMed ID: 9205746
[TBL] [Abstract][Full Text] [Related]
27. Acute toxicity studies of ebrotidine.
Grau MT; Romero A; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):490-1. PubMed ID: 9205750
[TBL] [Abstract][Full Text] [Related]
28. Chronic toxicity of ebrotidine in rats and dogs.
Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
Gedliczka O; Bobrzynski A; Rembiasz K; Fillat O; Torres J; Herrero E; Márquez M; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of ebrotidine in rats and dogs.
Albet C; Pérez JA; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
[TBL] [Abstract][Full Text] [Related]
31. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
Tulassay Z; Döbrönte Z; Farkas I; Juhász L; Simon L; Prónai L; Torres J; Márquez M
Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
Slomiany BL; Piotrowski J; Murty VL; Slomiany A
Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
[TBL] [Abstract][Full Text] [Related]
33. The antisecretory profile of action of the H2-receptor antagonists, famotidine, loxtidine, ranitidine and L-643,441 on the rat isolated gastric mucosa.
Reeves JJ; Stables R
Agents Actions; 1987 Feb; 20(1-2):22-8. PubMed ID: 2883848
[TBL] [Abstract][Full Text] [Related]
34. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
[TBL] [Abstract][Full Text] [Related]
36. Effects of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl] urea with potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers in rats.
Sekiguchi H; Hamada K; Taga F; Nishino K
Arzneimittelforschung; 1993 Feb; 43(2):134-8. PubMed ID: 8096133
[TBL] [Abstract][Full Text] [Related]
37. Endothelin-1, interleukin-4 and nitric oxide synthase modulators of gastric mucosal injury by indomethacin: effect of antiulcer agents.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Jun; 50(2):197-210. PubMed ID: 10424717
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of roxatidine against indomethacin-induced small intestinal mucosal injury in rats.
Umegaki E; Yoda Y; Tokioka S; Murano M; Higuchi K
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S35-40. PubMed ID: 20586863
[TBL] [Abstract][Full Text] [Related]
39. Gastroprotective and antisecretory effects of ebrotidine.
Konturek SJ; Maczka J; Kaminski K; Sito E; Torres J; Oleksy J
Scand J Gastroenterol; 1992 Jun; 27(6):438-42. PubMed ID: 1352908
[TBL] [Abstract][Full Text] [Related]
40. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
